# Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.

> **NCT04291209** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 80 (estimated)

## Conditions studied

- Ototoxic Hearing Loss

## Interventions

- **DRUG:** N-Acetyl Cysteine

## Key facts

- **NCT ID:** NCT04291209
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-26
- **Primary completion:** 2024-05-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-09-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04291209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04291209, "Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04291209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*